8-K: Elevai Labs and INmune Bio Amend License Agreement, Adjusting Tech Transfer Fee Payment Schedule

Elevai Labs and INmune Bio have amended their existing license agreement, modifying the payment schedule for the technology transfer fee.

Summary

• Elevai Labs and INmune Bio have amended their license agreement, which was originally effective January 15, 2024.
• The amendment primarily modifies the payment schedule for the technology transfer fee.
• The total tech transfer fee remains unchanged, but the payment schedule has been adjusted.
• An initial payment is due upon execution of the amendment, a second payment is due 14 months after the effective date, and the final payment is due upon completion of technology transfer or two years from the effective date, whichever is first.
• Technology transfer is considered complete upon successful completion of the first GMP manufactured batch of a licensed product.
• INmuneBio will provide support and troubleshooting to Elevai Labs even after the first GMP batch is completed, if requested.

Sentiment

Score: 7

Explanation: The document reflects a routine business update with a positive adjustment to payment terms. The lack of specific financial details and potential risks associated with technology transfer temper the overall sentiment.

Positives

• The amendment provides a revised payment schedule for the tech transfer fee, potentially easing the financial burden on Elevai Labs.
• INmuneBio's commitment to provide support and troubleshooting even after the first GMP batch is completed ensures continued collaboration and assistance for Elevai Labs.

Risks

• The document does not specify the exact amounts of the tech transfer fee, which are redacted, making it difficult to assess the financial impact.
• The completion of technology transfer is tied to the successful completion of the first GMP manufactured batch, which could be subject to delays or challenges.

Future Outlook

The amendment provides a revised payment schedule for the tech transfer fee, which may impact Elevai Labs' cash flow. The successful completion of the first GMP manufactured batch is a key milestone for the technology transfer.

Management Comments

• The parties acknowledge that this First Amendment and the Agreement set forth the entire understanding and intentions of the parties hereto as to the subject matter hereof and supersedes all previous understandings between the parties, written or oral, regarding such subject matter.

Industry Context

This amendment is specific to the agreement between Elevai Labs and INmune Bio and does not provide significant insight into broader industry trends. However, it highlights the importance of clear payment schedules and technology transfer milestones in licensing agreements within the biotechnology sector.

Comparison to Industry Standards

• It is common for biotech licensing agreements to include technology transfer fees and milestones.
• The specific payment schedule and terms are unique to this agreement and cannot be directly compared to other companies without more information.
• The redacted financial details make it difficult to assess the competitiveness of the agreement.

Stakeholder Impact

• The revised payment schedule may positively impact Elevai Labs' cash flow, benefiting shareholders.
• The continued collaboration with INmune Bio supports the development and commercialization of the licensed technology, which could benefit customers and other stakeholders.

Next Steps

• Elevai Labs will make the first payment of the tech transfer fee upon execution of the amendment.
• Elevai Labs will need to achieve the successful completion of the first GMP manufactured batch of a licensed product to complete the technology transfer.
• Elevai Labs will make the second payment 14 months after the effective date of the amendment.
• Elevai Labs will make the final payment upon completion of technology transfer or two years from the effective date, whichever is first.

Key Dates

Keywords

License Agreement, Tech Transfer Fee, Amendment, INmune Bio, Elevai Labs, GMP Manufacturing, Technology Transfer, Mesenchymal Stromal Cells